Leerink Partners Downgrades Reneo Pharmaceuticals to Market Perform

RPHMDelisted Stock  USD 18.20  1.40  8.33%   
About 55% of Reneo Pharmaceuticals' investors are presently thinking to get in. The analysis of current outlook of investing in Reneo Pharmaceuticals suggests that some traders are interested regarding Reneo Pharmaceuticals' prospects. Reneo Pharmaceuticals' investing sentiment overview a quick insight into current market opportunities from investing in Reneo Pharmaceuticals. Many technical investors use Reneo Pharmaceuticals stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
  
Leerink Partners analyst Joseph P. Schwartz downgraded Reneo Pharmaceuticals from Outperform to Market Perform with a price target of 1.00 . For an analyst ratings summary...

Read at streetinsider.com
Street Insider News
  

Reneo Pharmaceuticals Fundamental Analysis

We analyze Reneo Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Reneo Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Reneo Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Net Asset

Net Asset Comparative Analysis

Reneo Pharmaceuticals is currently under evaluation in net asset category among its peers. Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.

Reneo Pharmaceuticals Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Reneo Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Reneo Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Reneo Pharmaceuticals by comparing valuation metrics with similar companies.

Peers

Reneo Pharmaceuticals Related Equities

CNSPCns Pharmaceuticals   5.45   
0%
100.0%
PRMEPrime Medicine,   5.07   
0%
93.0%
CGEMCullinan Oncology   3.99   
0%
73.0%
CELCCelcuity LLC   2.79   
0%
51.0%
CCCCC4 Therapeutics   2.58   
0%
47.0%
NKTXNkarta   2.55   
0%
46.0%
KZRKezar Life   2.13   
0%
39.0%
HOWLWerewolf Therapeutics   1.95   
0%
35.0%
RPRXRoyalty Pharma   0.87   
0%
15.0%
ADPTAdaptive Biotechnologies   0.00   
0%
0%
SMMTSummit Therapeutics   0.00   
0%
0%
LEGNLegend Biotech   0.06   
1.0%
0%
HEPAHepion Pharmaceuticals   0.20   
3.0%
0%
VIRVir Biotechnology   0.41   
7.0%
0%
IMMXImmix Biopharma   0.92   
16.0%
0%
DNAGinkgo Bioworks   0.95   
17.0%
0%
APLSApellis Pharmaceuticals   1.11   
20.0%
0%
EWTXEdgewise Therapeutics   1.20   
22.0%
0%
KRONKronos Bio   3.16   
57.0%
0%
OCEAOcean Biomedical   3.22   
59.0%
0%
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate.
You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.

Other Consideration for investing in Reneo Stock

If you are still planning to invest in Reneo Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Reneo Pharmaceuticals' history and understand the potential risks before investing.
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets